We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
But8.5
Butyrate Research
Likely helpsHigh safety
71 peer-reviewed studies
What the evidence says
Likely helps
Butyrate appears to help in 11 of 11 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 2018–2026 with a typical study size of 66 participants.
Based on 71 studies · 13 meta-analyses · 19 RCTs · 49,112 total participants
Confidence
High
What the studies found
11helped· 60 more without graded effect data
By outcome
Digestive healthImproved gut lining integrity and reduced GI discomfort within 2-4 weeks · 2-4 weeks
Likely helps64 studies
Therapeutic & clinical
Likely helps14 studies
InflammationImproved gut barrier and reduced inflammation · 2-4 weeks
Mostly mechanism / observational6 studies
Glucose & metabolicSCFA supporting insulin sensitivity and mitochondrial function · 4-8 weeks
Mostly mechanism / observational6 studies
Heart & blood pressure
Mostly mechanism / observational4 studies
Weight management
Mostly mechanism / observational3 studies
Cognitive function
Mostly mechanism / observational3 studies
Depression & mood
Mostly mechanism / observational3 studies
Immune supportStrengthens gut barrier integrity and modulates immune response · 4-8 weeks
Mostly mechanism / observational3 studies
Cholesterol & lipids
Mostly mechanism / observational3 studies
Anxiety & stress
Too few graded studies2 studies
Bone health
Too few graded studies2 studies
Safety profile
Too few graded studies2 studies
Skin health
Too few graded studies1 study
By the numbers
Pulled from 50 studies with measurable effects
Likely real effects
57%
across studies
People studied
49k
typical study: 66 people
Strongest designs
32
13 pooled, 19 randomised
Showed benefit
100%
11/11 studies
How long studies ran
1–4 weeks
1
1–3 months
1
Populations Studied
General population2
Adults2
Chronic kidney disease patients1
Patients with depressive disorder1
Active research area
62 studies in the last 5 years · Latest meta-analysis: 2026
20182026
1Circulating acetate and propionate levelsMeta-Analysisn=9,661 · very large study2026
CKD is associated with a profound systemic reduction in acetate and propionate, supporting the model of a compromised gut-kidney axis based on converging evidence.
Thakur D et al. · Nutrients (2026)
Borderline
Quantitative synthesis revealed a significant and consistent systemic depletion of circulating acetate and propionate in adult CKD patients compared to healthy controls (p < 0.05).
CKD is associated with a profound systemic reduction in acetate and propionate, supporting the model of a compromised gut-kidney axis based on converging evidence.
The divergent results for butyrate in paediatric versus adult populations suggest that SCFA metabolism is influenced by age-related factors or compensatory mechanisms.
2Chao1 diversity indexMeta-AnalysisCited 86×n=2,091 · very large study2023
This meta-analysis examined the effects of Butyrate.
Gao M et al. · Translational psychiatry (2023)
Noticeable benefit
← WorseNo effectBetter →
A random-effects model with restricted maximum-likelihood estimator was used to synthesize the effect size (assessed by standardized mean difference [SMD]) across studies.
In subgroup analyses with regional variations(east/west) as a predictor, patients who were in the West had a lower Chao1 level (SMD -0.42[-0.74 to -0.10]).
Subgroup meta-analysis showed Firmicutes level was decreased in patients with depressive disorder who were medication-free (SMD -1.54[-2.36 to -0.72]), but Bacteroidetes level was increased (SMD -0.90[0.07 to 1.72]).
3Phylogenetic diversity in psychiatric disordersMeta-AnalysisCited 534×n=1,519 · large study2021
This systematic review and meta-analysis found that gut microbiota perturbations were associated with a transdiagnostic pattern with a depletion of certain anti-inflammatory butyrate-producing bacteria and an enrichment of pro-inflammatory bacteria in patients with depression, bipolar disorder, schizophrenia, and anxiety.
Nikolova VL et al. · JAMA psychiatry (2021)
Noticeable benefit
← WorseNo effectBetter →
There was a small decrease in phylogenetic diversity (SMD = -0.24; 95% CI, -0.47 to -0.001) and no significant differences in Shannon and Simpson indices.
5Gut microbiota composition in psychiatric disordersSystematic ReviewCited 374×n=2,510 · very large study2022
This systematic-review examined the effects of Butyrate.
McGuinness AJ et al. · Molecular psychiatry (2022)
We also observed substantial heterogeneity across studies with regards to methodologies and reporting.
Further prospective and experimental research using new tools and robust guidelines hold promise for improving our understanding of the role of the gut microbiota in mental and brain health and the development of interventions based on modification of gut microbiota.
6Meta-AnalysisCited 482×n=2,099 · very large study2018
Dietary fiber intervention, particularly involving fructans and galacto-oligosaccharides, leads to higher fecal abundance of Bifidobacterium and Lactobacillus spp. but does not affect α-diversity.
So D et al. · The American journal of clinical nutrition (2018)
Dietary fiber intervention, particularly involving fructans and galacto-oligosaccharides, leads to higher fecal abundance of Bifidobacterium and Lactobacillus spp. but does not affect α-diversity.
Further research is required to better understand the role of individual fiber types on the growth of microbes and the overall gut microbial community.
This review was registered at PROSPERO as CRD42016053101.
7Biologics response prediction in IBDSystematic ReviewCited 36×n=38 · small study2024
IBD patients who responded well to vedolizumab treatment had higher levels of specific bacteria that produce butyrate, along with increased levels of metabolites such as butyrate, branched-chain am...
Wang C et al. · Microbiological research (2024)
IBD patients who responded well to vedolizumab treatment had higher levels of specific bacteria that produce butyrate, along with increased levels of metabolites such as butyrate, branched-chain amino acids and acetamide following vedolizumab treatment.
Crohn's disease patients who responded positively to ustekinumab treatment showed higher levels of Faecalibacterium and lower levels of Escherichia/Shigella.
Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Sasaki M et al. · Allergy (2024)
Overall, there was some evidence showing that the three main SCFAs (acetate, propionate and butyrate) in the first few years of life had a protective effect against allergic diseases, especially for atopic dermatitis, wheeze or asthma and IgE-mediated food allergy in childhood.
The association between each SCFA and allergic disease appeared to be different by disease and the age of assessment.
Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Our research found universally applicable biomarkers and investigated their potential roles in promoting human health at high altitudes.
Zhao H et al. · Gut microbes (2024)
Functional analysis and qPCR revealed that butyrate may be a functional metabolite in high-altitude adaptation.
A high-altitude rat model showed that butyrate reduced intestinal damage caused by high altitudes.
According to cell experiments, butyrate may downregulate hypoxia-inducible factor-1α (HIF-1α) expression and blunt cellular responses to hypoxic stress.
In this study, we demonstrated that the promising substate (prebiotics), microbe (probiotics), metabolite (postbiotics), and target are suitable for obsesity treatment, providing a microbiome basis for further research.
Oh KK et al. · Cells (2022)
Then, we implemented protein-protein interaction (PPI) networks with 342 overlapping target, another subnetwork was constructed with the top 30% degree centrality (DC), and the final core networks were obtained after screening the top 30% betweenness centrality (BC).
The final core targets were IL6, AKT1, and ALB.
We showed that the three core targets interacted with three other components via the MSMT network in alleviating obesity, i.e., four microbiota, two substrates, and six metabolites.
Although a definitive interpretation is limited by the cross-sectional design of published reports, we integrated findings of microbial composition and downstream functional pathways and metabolites, offering possible explanations regarding age-related processes.
Badal VD et al. · Nutrients (2020)
Beta diversity distances significantly differed across various developmental stages and were different even between oldest-old and younger-old adults.
Differences in taxonomic composition and functional potential varied across studies, but Akkermansia was most consistently reported to be relatively more abundant with aging, whereas Faecalibacterium, Bacteroidaceae, and Lachnospiraceae were relatively reduced.
Although a definitive interpretation is limited by the cross-sectional design of published reports, we integrated findings of microbial composition and downstream functional pathways and metabolites, offering possible explanations regarding age-related processes.
Integrating these personalised, evidence-informed protocols may support the optimisation of physiological resilience and performance.
Biliński K et al. · Nutrients (2026)
These SCFAs serve as energy substrates that may enhance glucose uptake, lipid oxidation, and glycogen storage in skeletal muscle.
Evidence suggests that travel-related stressors-including dehydration, psychological stress, and shifts toward highly processed diets-further exacerbate the loss of beneficial taxa.
To mitigate these effects, this article proposes evidence-informed strategies: timed light exposure to reset the master clock, chronobiotic meal timing to entrain peripheral tissues, and targeted symbiotic supplementation to restore SCFA-producing populations.
13Efficacy of sodium butyrate formulations in intestinal diseasesSystematic Review2026
Differences between clinical study results suggests that formulation of butyrate impacts its efficacy.
Caban M et al. · Digestive diseases and sciences (2026)
Therefore, we suggest that clinical results should be assessed in relation to specific preparations.
Our summary confirms that specific microencapsulated versions, including those utilizing the MSB® technology are valuable therapeutic options supporting the treatment of intestinal diseases.
Differences between clinical study results suggests that formulation of butyrate impacts its efficacy.
Byun AS et al. · Frontiers in bioscience (Landmark edition) (2026)
The purpose is to restore gut microbial homeostasis.
It is posited that such adjunctive treatments may significantly influence the lung microbiota epigenome by positively impacting the balance of microorganisms within the lung, restoring eubiosis and consequently health.
Ibeas-Pérez MV, Agüí-Ruiz B, Arias-Sánchez S, Martín-Monzón I. · Frontiers in molecular neuroscience (2026)
The Mediterranean Diet appears to exert a neuroprotective role in disorders such as mild cognitive impairment, schizophrenia, Parkinson's disease, and metabolic diseases.
This protective function, derived from changes in the gut microbiota, leads to improvements in cognitive function.
Overall, the findings underscore the direct relationship between nutrition and mental health and reinforce the value of the Mediterranean Diet as a preventive strategy and a modulator of cognition through the gut-brain axis, promoting brain health across the lifespan.
Published by Portland Press Limited on behalf of the Biochemical Society.
Sun QQ et al. · Clinical science (London, England : 1979) (2026)
Lipids are indispensable architectural and functional components of central nervous system (CNS) myelin, with cholesterol, sphingolipids, and phospholipids collectively constituting 70%-80% of myelin membrane composition.
We further synthesize emerging therapeutic strategies targeting these pathways, including immunometabolism modulators, precision lipid interventions; diet-microbiome synergies: ketogenic diets combined with butyrate-producing probiotics to amplify endogenous remyelination.
By integrating lipidomics datasets and recent clinical trial evidence, we propose a shift from broad metabolic suppression to spatially resolved modulation of lipid flux.
18Gut-brain health and systemic inflammationSystematic Review2026
Therapeutic strategies that restore BPB populations and butyrate levels, such as prebiotics, dietary fiber, and microbiota-targeted interventions, hold promise for mitigating inflammation and enhancing systemic health through microbiome modulation.
Snodgrass JL et al. · International journal of molecular sciences (2026)
Butyrate supports colonocyte energy metabolism, reinforces epithelial barrier function, regulates goblet cell mucus production, and exerts anti-inflammatory effects via histone deacetylase inhibition and G-protein-coupled receptor signaling.
The depletion of BPB and the resultant butyrate deficiency may represent a unifying pathophysiological mechanism underlying these conditions.
Therapeutic strategies that restore BPB populations and butyrate levels, such as prebiotics, dietary fiber, and microbiota-targeted interventions, hold promise for mitigating inflammation and enhancing systemic health through microbiome modulation.
19gut microbiota and short-chain fatty acids in cardiometabolic HFpEFSystematic Review2026
Targeting gut-heart axis and SCFAs pathways may represent a biologically plausible and low-risk approach that could help attenuate inflammation and metabolic dysfunctions in patients with cardiometabolic HFpEF, offering novel potential therapeutic targets for their management.
This review summarizes current evidence linking gut microbiota dysfunction to cardiometabolic HFpEF, elucidates the mechanistic role of SCFAs, and discusses nutritional approaches aimed at enhancing their production and activity.
Targeting gut-heart axis and SCFAs pathways may represent a biologically plausible and low-risk approach that could help attenuate inflammation and metabolic dysfunctions in patients with cardiometabolic HFpEF, offering novel potential therapeutic targets for their management.
20Exercise effects on gut microbiome composition and health outcomesSystematic Review2026
Future research requires diet-controlled randomized controlled trials with ≥12-week interventions, shotgun metagenomics, and mechanistic validation of the gut-muscle axis in humans.
Alsinani Y et al. · Nutrients (2026)
Emerging evidence supports the gut-muscle axis in sarcopenia and personalized exercise prescription guided by microbiome profiling.
Conclusion: Exercise shows promise as a low-cost modulator of the gut microbiome for enriching health-associated taxa and improving metabolic outcomes.
Definitive evidence linking exercise-induced microbial shifts to enhanced athletic performance in humans remains lacking.